Lessons from tumor reversion for cancer treatment

Amson, Robert; Karp, Judith E.; Telerman, Adam

doi:10.1097/cco.0b013e32835b7d21

Cited by 59 publications

(67 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instrumental in this was the experimental 'tumour reversion model' developed by the Telerman group (Telerman and Amson 2009;Tuynder et al 2002Tuynder et al , 2004. Naturally, the cancer aspect of TCTP's 'function' has recently attracted increasing attention, as documented by the about 40 papers and 6 review articles (Telerman and Amson 2009;Bommer 2012;Acunzo et al 2014;Amson et al 2013Amson et al , 2011Chan et al 2012a;Efferth 2006;Koziol and Gurdon 2012) on 'TCTP and cancer' that appeared only within the last 10 years.…”

Section: The 'Translationally Controlled Tumour Protein Tctp': Names mentioning

confidence: 99%

“…Last but not least, the frequent reports on TCTP overexpression in cancer cells and human tumours (reviewed in Bommer 2012; Acunzo et al 2014;Chan et al 2012a;Koziol and Gurdon 2012) and on its down-regulation in the tumour reversion model (Telerman and Amson 2009;Amson et al 2013) provide additional compelling evidence that TCTP is a growth-promoting protein. These aspects are discussed below, in Sect.…”

Section: Tctp and Cell Growth Regulationmentioning

confidence: 99%

“…However, since the beginning of this century, a substantial body of evidence has been accumulated, demonstrating that TCTP is indeed overexpressed in cancer cells and in human tumours. A number of review articles have summarised these efforts (Telerman and Amson 2009;Bommer 2012;Acunzo et al 2014;Amson et al 2013;Chan et al 2012a;Koziol and Gurdon 2012), and the reader is referred to these for papers reporting overexpression of TCTP in cancer cell lines. Kaarbo et al (2013) those papers, which have dealt specifically with one specific type of cancer.…”

Section: Overexpression Of Tctp In Human Tumoursmentioning

confidence: 99%

“…Given the well-established role of TCTP in cancer as summarised in this section, it is not surprising that the idea of exploring TCTP as an anticancer target protein is not new, and this interesting topic has already been covered in six review articles (Telerman and Amson 2009;Bommer 2012;Acunzo et al 2014;Amson et al 2013;Efferth 2005Efferth , 2006. Here I will briefly summarise these efforts, according to the groups of drugs investigated to target TCTP:…”

Section: Tctp As An Anticancer Targetmentioning

confidence: 99%

“…All these drugs bind to TCTP and disrupt its interaction with other partner proteins, eventually leading to increased release of the protein from the cell and to lowered intracellular TCTP levels (Telerman and Amson 2009). Since the demonstration of the reciprocal repressive feedback loop between TCTP and the tumour suppressor P53 by the same laboratory (Amson et al 2012), the mechanism of action of these drugs can be described in more detail as follows (Amson et al 2013): Binding of sertraline and thioridazine to TCTP prevents its binding to MDM2 and consequently the destabilisation of P53. The resulting increased P53 levels lead to additional transcriptional inhibition of TCTP expression.…”

Section: Tctp As An Anticancer Targetmentioning

confidence: 99%

See 4 more Smart Citations

The Translational Controlled Tumour Protein TCTP: Biological Functions and Regulation

Bommer

2017

Results and Problems in Cell Differentiation

View full text Add to dashboard Cite

The Translational Controlled Tumour Protein TCTP (gene symbol TPT1, also called P21, P23, Q23, fortilin or histamine-releasing factor, HRF) is a highly conserved protein present in essentially all eukaryotic organisms and involved in many fundamental cell biological and disease processes. It was first discovered about 35 years ago, and it took an extended period of time for its multiple functions to be revealed, and even today we do not yet fully understand all the details. Having witnessed most of this history, in this chapter, I give a brief overview and review the current knowledge on the structure, biological functions, disease involvements and cellular regulation of this protein. TCTP is able to interact with a large number of other proteins and is therefore involved in many core cell biological processes, predominantly in the response to cellular stresses, such as oxidative stress, heat shock, genotoxic stress, imbalance of ion metabolism as well as other conditions. Mechanistically, TCTP acts as an anti-apoptotic protein, and it is involved in DNA-damage repair and in cellular autophagy. Thus, broadly speaking, TCTP can be considered a cytoprotective protein. In addition, TCTP facilitates cell division through stabilising the mitotic spindle and cell growth through modulating growth signalling pathways and through its interaction with the proteosynthetic machinery of the cell. Due to its activities, both as an anti-apoptotic protein and in promoting cell growth and division, TCTP is also essential in the early development of both animals and plants. Apart from its involvement in various biological processes at the cellular level, TCTP can also act as an extracellular protein and as such has been involved in modulating whole-body defence processes, namely in the mammalian immune system. Extracellular TCTP, typically in its dimerised form, is able to induce the release of cytokines and other signalling molecules from various types of immune cells. There are also several examples, where TCTP was shown to be involved in antiviral/antibacterial defence in lower animals. In plants, the protein appears to have a protective effect against phytotoxic stresses, such as flooding, draught, too high or low temperature, salt stress or exposure to heavy metals. The finding for the latter stress condition is corroborated by earlier reports that TCTP levels are considerably up-regulated upon exposure of earthworms to high levels of heavy metals. Given the involvement of TCTP in many biological processes aimed at maintaining cellular or whole-body homeostasis, it is not surprising that dysregulation of TCTP levels may promote a range of disease processes, foremost cancer. Indeed a large body of evidence now supports a role of TCTP in at least the most predominant types of human cancers. Typically, this can be ascribed to both the anti-apoptotic activity of the protein and to its function in promoting cell growth and division. However, TCTP also appears to be involved in the later stages of cancer progression, such ...

show abstract

Section: The 'Translationally Controlled Tumour Protein Tctp': Names mentioning

confidence: 99%

Section: Tctp and Cell Growth Regulationmentioning

confidence: 99%

Section: Overexpression Of Tctp In Human Tumoursmentioning

confidence: 99%

Section: Tctp As An Anticancer Targetmentioning

confidence: 99%

Section: Tctp As An Anticancer Targetmentioning

confidence: 99%

See 3 more Smart Citations

The Translational Controlled Tumour Protein TCTP: Biological Functions and Regulation

Bommer

2017

Results and Problems in Cell Differentiation

View full text Add to dashboard Cite

show abstract

Revisiting the Molecular Interactions between the Tumor Protein TCTP and the Drugs Sertraline/Thioridazine

et al. 2021

View full text Add to dashboard Cite

show abstract

Building Customizable Multisite‐Targeting c‐Myc shRNA Array into Branch‐PCR‐Constructed DNA Nanovectors for Enhanced Tumor Cell Suppression

Cheng

et al. 2020

ChemistrySelect

View full text Add to dashboard Cite

RNA interference (RNAi) has been extensively used to downregulate abnormal excessive mRNA in treating intractable diseases like cancers. Albeit with the success of siRNA drugs, the development of shRNA (small hairpin RNA) as RNAi drugs still meets the great challenge in clinical treatments for lacking the suitable delivery vector to express numerous shRNAs in cells. Considering our previously established branch‐PCR (branched polymerase chain reaction) technology, we herein introduced a multisite‐targeting c‐Myc shRNA array into DNA nanovectors via branch‐PCR. The results indicated that this kind of DNA nanovector retained better serum stability than plasmids and linear DNA. The cell viability test further showed that the transcription of c‐Myc shRNA arrays greatly enhanced the anti‐cancer activity by eliminating approximately 98.2 % c‐Myc mRNA, which posed a technical advance in augmenting the gene silencing efficiency of vector‐expressed shRNAs in cells. Hence, it would be promising to use this customizable and stable shRNA array‐based DNA nanovectors to enhance the curable efficacy of shRNAs in cancer treatment.

show abstract

Lessons from tumor reversion for cancer treatment

Abstract: In this review, we discuss some of these reversion pathways and how this approach could open a new route to cancer treatment.

Cited by 59 publications

References 53 publications

The Translational Controlled Tumour Protein TCTP: Biological Functions and Regulation

The Translational Controlled Tumour Protein TCTP: Biological Functions and Regulation

Revisiting the Molecular Interactions between the Tumor Protein TCTP and the Drugs Sertraline/Thioridazine

Building Customizable Multisite‐Targeting c‐Myc shRNA Array into Branch‐PCR‐Constructed DNA Nanovectors for Enhanced Tumor Cell Suppression

Contact Info

Product

Resources

About